Patients with high risk prostate cancer may benefit 'equally' from two new treatments

(European Society for Medical Oncology) Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid.